ADVFN Logo ADVFN

Não encontramos resultados para:
Verifique se escreveu corretamente ou tente ampliar sua busca.

Tendências Agora

Rankings

Parece que você não está logado.
Clique no botão abaixo para fazer login e ver seu histórico recente.

Cadastre-se

Já é membro? Faça login

Moneta Markets

Abrir Conta

Moneta Markets
Dados
Notícias
Ferramentas
Mercados
Comunidade

Recursos principais

Follow Feed

Conecte-se com traders e investidores em nossa comunidade Follow Feed.

Fluxo de Opções

Explore dados abrangentes de opções e utilize filtros avançados com Fluxo de Opções.

Monitor

Organize e monitore sua lista de ações e ativos com o Monitor.
AI Entrar Premium IconPremium Help Menu
Índice Bovespa
118.532,68
-1,33%
S&P 500
5.942,47
1,26%
US Dollar vs BRL
6,1822
0,00%
Bitcoin
97.814,96
-0,40%
Brent Oil
76,495
0,00%
As Melhores Corretoras Online
Registration Strip Icon for tools Aumente o nível de sua negociação com nossas ferramentas poderosas e insights em tempo real, tudo em um só lugar.
Cadastre-se
  1. Início
  2. Investir
  3. Ações
  4. EUA
  5. NASDAQ
  6. XBiotech Inc (XBIT)

  7. XBiotech Inc (XBIT) Notícias

XBIT

XBiotech (XBIT)

XBiotech Inc
De:
Ordenação:
 Apresentando as notícias mais relevantes sobre:NASDAQ:XBIT
DataHoraFonteTítuloCódigoCompanhia
31/12/202417:22Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:XBITXBiotech Inc
23/12/202411:00GlobeNewswire Inc.XBiotech Pauses Rheumatology programNASDAQ:XBITXBiotech Inc
13/11/202417:12Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:XBITXBiotech Inc
18/06/202412:35GlobeNewswire Inc.XBiotech Results from Randomized Double-Blinded Phase 1/2 Study Suggest Potential Breakthrough Treatment for Advanced Pancreatic CancerNASDAQ:XBITXBiotech Inc
07/02/202414:36Edgar (US Regulatory)Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]NASDAQ:XBITXBiotech Inc
05/01/202412:48Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:XBITXBiotech Inc
04/01/202411:00GlobeNewswire Inc.XBiotech to Begin Constructing New R&D Facility on its 48-acre CampusNASDAQ:XBITXBiotech Inc
14/11/202311:00GlobeNewswire Inc.Dr. Alan Kivitz to Chair XBiotech’s Natrunix Program in Rheumatoid ArthritisNASDAQ:XBITXBiotech Inc
26/09/202310:00GlobeNewswire Inc.XBiotech Announces Enrollment Completion of Phase I Clinical Trial for Hutrukin, a Novel Candidate Therapy for StrokeNASDAQ:XBITXBiotech Inc
30/08/202310:00GlobeNewswire Inc.XBiotech Announces Enrollment Completion of Phase II, Placebo Controlled, Multicenter Study for Natrunix in Pancreatic CancerNASDAQ:XBITXBiotech Inc
08/08/202312:47GlobeNewswire Inc.XBiotech Announces First Patient Begins Novel Natrunix Therapy in Phase II Rheumatoid Arthritis (RA) Clinical TrialNASDAQ:XBITXBiotech Inc
26/06/202309:48Edgar (US Regulatory)Statement of Changes in Beneficial Ownership (4)NASDAQ:XBITXBiotech Inc
23/06/202316:04Edgar (US Regulatory)Current Report Filing (8-k)NASDAQ:XBITXBiotech Inc
20/06/202310:20Edgar (US Regulatory)Amended Tender Offer Statement by Issuer (sc To-i/a)NASDAQ:XBITXBiotech Inc
22/05/202310:00GlobeNewswire Inc.FDA Authorizes Phase II Study for Natrunix in Rheumatoid Arthritis PatientsNASDAQ:XBITXBiotech Inc
17/05/202310:22Edgar (US Regulatory)Tender Offer Statement by Issuer (sc To-i)NASDAQ:XBITXBiotech Inc
17/05/202310:00GlobeNewswire Inc.XBiotech Commences Tender Offer to Purchase up to $80,000,000 Worth of Its SharesNASDAQ:XBITXBiotech Inc
10/05/202316:42Edgar (US Regulatory)Quarterly Report (10-q)NASDAQ:XBITXBiotech Inc
28/04/202313:38Edgar (US Regulatory)Annual Report to Security Holders (ars)NASDAQ:XBITXBiotech Inc
28/04/202313:33Edgar (US Regulatory)Additional Proxy Soliciting Materials (definitive) (defa14a)NASDAQ:XBITXBiotech Inc
10/02/202314:22Edgar (US Regulatory)Statement of Ownership (sc 13g)NASDAQ:XBITXBiotech Inc
13/10/202213:46GlobeNewswire Inc.XBiotech Announces First Patient Enrolled into the French National Cancer Institute (INCA) Sponsored Phase I/II/III Clinical Study for Natrunix™ Therapy for Colorectal CancerNASDAQ:XBITXBiotech Inc
20/06/202210:00GlobeNewswire Inc.XBiotech Announces Successful Completion of Phase I portion of Pancreatic Cancer StudyNASDAQ:XBITXBiotech Inc
13/05/202216:17Edgar (US Regulatory)Proxy Statement (definitive) (def 14a)NASDAQ:XBITXBiotech Inc
28/04/202210:00GlobeNewswire Inc.XBiotech Announces French National Agency (ANSM) Approval and National Cancer Institute (INSA) funding to Support Phase I/II/III Clinical Study for Natrunix™ in Combination with Trifluridine/Tipiracil (TASKIN) for Treatment of Metastatic Colorectal CanceNASDAQ:XBITXBiotech Inc
15/03/202218:02Edgar (US Regulatory)Annual Report (10-k)NASDAQ:XBITXBiotech Inc
02/02/202211:00GlobeNewswire Inc.XBiotech Inks Clinical Manufacturing DealNASDAQ:XBITXBiotech Inc
13/12/202110:00GlobeNewswire Inc.FDA Approves XBiotech’s IND in RheumatologyNASDAQ:XBITXBiotech Inc
28/10/202112:59GlobeNewswire Inc.XBiotech to Launch Novel Candidate Therapy for StrokeNASDAQ:XBITXBiotech Inc
08/09/202110:00GlobeNewswire Inc.Dr. Benjamin Musher to Chair Phase 1-2 Study Evaluating XBiotech’s Natrunix™ Anti-Cancer Therapy in Pancreatic CancerNASDAQ:XBITXBiotech Inc
 Apresentando as notícias mais relevantes sobre:NASDAQ:XBIT

Seu Histórico Recente

BOV
PRIO3
PETRORIO ON
BOV
IBOV
Índice Bovespa
BOV
PCAR3
PÃO DE AÇUCAR ON
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

Brasil
Empresa
Negócios
Popular
Obter o aplicativo
App Store
Google Play

Suporte: (11) 4950 5808 | suporte@advfn.com.br

Ao acessar os serviços da ADVFN você estará de acordo com os Termos e Condições

© 2025 ADVFN PLC - Todos os direitos reservados